Swedish SPC approved for less than 50% of human medicinal products

Fimea reminds marketing authorisation and registration holders of the requirement to submit a Swedish Summary of Product characteristics by 9 February 2022.

To date, the Swedish SPC has been submitted and approved for 47,8% of all medicinal products for human use and 31.6% of veterinary medicinal products.

https://www.fimea.fi/-/myyntiluvallisella-laakkeella-ja-rekisteroidylla-perinteisella-kasvirohdosvalmisteella-on-oltava-myos-ruotsinkielinen-valmisteyhteenveto-9.2.2022-mennessa